Cervical Cancer: Page 2

Dr. Elizabeth Stern: A pioneer in cytopathology screening

Early years

March 28, 2022

Hologic receives CE Mark for Genius cervical cancer software

The new algorithm analyzes ThinPrep Pap images to narrow tens of thousands of cells down to an AI-generated gallery to find lesions and cancer cells. This arms healthcare providers with the critical information they need to guide earlier detection and better treatment decisions for the patients in their care, the company said.

November 3, 2021

How AI for cervical cancer can help achieve healthcare equity

Thanks to screening programs and improvements in technology, mortality rates have been falling in high-income countries, yet rates within these regions still can affect populations drastically differently. For example, Black women in the U.S. are two times more likely to die from cervical cancer than white women.3

October 10, 2021

Mel-Mont validates self-sampling kit

Norwegian researchers tested the kit's performance in a group of 500 women at detecting rates of genital HPV infection compared to clinician-collected samples. The study found "fair agreement" of HPV positivity rates between the two methods, according to the authors. The study was published in BMC Infectious Diseases.

August 4, 2021

OptraScan launches cytology slide scanning device

CytoSiA consists of the company's digital pathology scanner, storage, and artificial intelligence (AI) algorithms for screening and detection of cervical cancer, precancerous lesions, and atypical cells. It can scan 15 x 15-mm cytology slides at 40x magnification in less than 60 sec, according to the firm.

May 24, 2021

Hologic wins CE Mark for cervical cancer screening system

After analyzing all cells on a ThinPrep Pap test slide, Genius Digital Diagnostics can provide a gallery view of the most diagnostically relevant images, Hologic said.

November 16, 2020

ACS cervical cancer guidelines disappoint some testing firms

The current standard of care is to use the Pap test for women ages 21 to 29 and a combination of both the Pap test and HPV test (cotesting) for women between the ages of 30 and 65. The ACS guidelines, which were published July 30, would shift to HPV testing only, and Hologic claims this would erode access to preventative healthcare and could sow confusion among women and their healthcare providers.

July 30, 2020

National cervical cancer screening guidelines shift to primary HPV testing

The ACS published a 2020 update to guidelines for cervical cancer screening for individuals at average risk in its publication CA: A Cancer Journal for Clinicians online July 30. Guidelines were last updated in 2012.

July 30, 2020

HPV, Pap cotesting best for cervical cancer detection in Quest study

Cotesting involves Pap and HPV screening using the same specimen. A new study of women 30 years or older by researchers at Quest Diagnostics and the University of Pittsburgh Medical Center found that cotesting outperformed HPV or Pap testing alone for detecting precancer or cancer. In the retrospective study, the researchers evaluated deidentified results for tests conducted between 2010 and 2018 by Quest in 13.6 million women; 8,059 had precancers and 1,259 were subsequently diagnosed with cervical cancer.

July 8, 2020

Machine learning could 'transform' cervical cancer screening, NCI researchers report

The NCI researchers described positive experiences with Cytoreader, an automated system for evaluating digital dual-stained whole-slide images for the protein biomarkers p16 and Ki-67, using data from three epidemiology studies of patients with cervical and anal cancers who were positive for human papillomavirus (HPV). The automated system assesses the number of dual-stained positive cells and flags the ones that exceed predefined cutoff points.

June 25, 2020

Could cervical cancer be eliminated in 20 years?

The findings suggest a way for the U.S. clinical community to actively respond to the World Health Organization's (WHO) 2018 charge to eliminate cervical cancer as a public health problem, wrote a team led by Emily Burger, PhD, of the Harvard T.H. Chan School of Public Health in Boston. The WHO's cervical cancer incidence target is four or fewer cases per 100,000 women-years.

February 10, 2020

Becton Dickinson files for Onclarity FDA approval in 11 more HPV types

The Onclarity test is currently approved for detecting the three HPV genotypes -- 16, 18, and 45 -- that cause most cases of cervical cancer and precancer. However, the test detects 14 high-risk forms of HPV, according to Becton Dickinson, and the PMA filing seeks approval for 11 additional types, including types 31, 51, and 52. In a statement, the company explained that while HPV types 16, 18, and 45 have traditionally caused most cases of cervical cancer, they are becoming less common due to HPV vaccination in younger populations.

November 13, 2019

Previous Page

Page 2 of 3

Next Page